Clinical trials: Dysthyroid Orbitopathy
Graves Ophthalmopathy
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease).
- Trial name
- NCT01114503
- Testing
- Otelixizumab - low dose, Otelixizumab - medium low dose, Otelixizumab - medium high dose
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Thyroid Eye Disease, Graves Ophthalmopathy
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment…
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
- Trial name
- Teprotumumab (NCT06275373)
- Testing
- Teprotumumab Injection [Tepezza]
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Dry Eye Disease (DED), Graves Ophthalmopathy
Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves Disease
This prospective, interventional, randomized, controlled, double-blind clinical study evaluates the effect of Low-Level Light Therapy (LLLT) delivered by a polychromatic periocular mask (Eye-light®️) versus a sham device in…
- Trial name
- LLLT-Graves (NCT07332988)
- Testing
- Low Light Level therapy
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Tocilizumab, Thyroid Associated Ophthalmopathy
Efficacy and Safety of Tocilizumab for TAO
This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.
- Trial name
- NCT06087731
- Testing
- Tocilizumab
- Where
- China
- Sponsor
- Sun Yat-sen University
Thyroid-Associated Ophthalmopathy
Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT06585592
- Volunteers
- 500 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Associated Ophthalmopathy
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
This is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages.
- Trial name
- NCT06269393
- Testing
- IBI311
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking University People's Hospital
Graves Ophthalmopathy
Sirolimus in Graves' Orbitopathy
Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast…
- Trial name
- RETROSIRGO (NCT05345119)
- Testing
- Sirolimus, Methylprednisolone
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Thyroid Associated Ophthalmopathies
Selenium in Mild Thyroid Eye Disease in North America
The purpose of this study is to determine whether sodium selenite is helpful in the treatment of mild thyroid eye disease in North America.
- Trial name
- S-ITEDS (NCT02112643)
- Testing
- Sodium selenate, Sugar pill
- Sponsor
- Columbia University
Thyroid Associated Ophthalmopathies
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152366
- Testing
- IBI311, Glucocorticoids
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Associated Ophthalmopathy, Surgical Procedure, Unspecified
Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.
This is a multicentric, randomized, single-blinded clinical trial to evaluate the efficacy and safety of 3D printing for the planification and simulation of orbital decompression surgery for thyroid-associated orbitopathy.
- Trial name
- NCT04662190
- Testing
- 3D printing model/guide., Standard surgery
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Althaia Xarxa Assistencial Universitària de Manresa
Graves Ophthalmopathy
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
Grave's ophthalmopathy is the most common cause of orbital disease in adults. The clinical presentation may vary between sub clinic symptoms to severe ones.
- Trial name
- NCT01999790
- Testing
- blepharotomy, posterior approach
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Thyroid-associated Ophthalmopathy
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
Thyroid-associated ophthalmopathy (TAO) is an autoimmune process that can affect the orbital and periorbital tissues and the thyroid gland.
- Trial name
- NCT01599273
- Testing
- subconjunctival triamcinolone injection
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Thyroid Eye Disease, Eyelid Diseases
Tamsulosin for Thyroid Lid Retraction
The purpose of this study is to examine the effect of using Tamsulosin for treatment of eyelid retraction as part of thyroid eye disease.
- Trial name
- NCT04359979
- Testing
- Tamsulosin
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Thyroid Eye Disease
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED).
- Trial name
- NCT07265258
- Testing
- Teprotumumab N01, Methylprednisolone
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Bioavailability, Bioequivalence
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
- Trial name
- NCT06563856
- Testing
- TEPEZZA, EDP
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease
ASTED (Antioxidant Supplements for TED) trial is an investigator-initiated, randomized, triple masked, clinical trial of a selected combination of vitamins and minerals versus placebo in patients with moderate to severe thyroid…
- Trial name
- NCT02422368
- Testing
- Methylprednisolone + ASTED
- Where
- 2 sites in Iran
- Sponsor
- Iran University of Medical Sciences
Thyroid Eye Disease, Vasculitis
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
This is a pilot study to investigate serum prednisolone profiles in: Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.
- Conditions
- Thyroid Eye Disease, Vasculitis, COPD Exacerbation Acute, Asthma
- Trial name
- EHD-Pred PK (NCT05012033)
- Testing
- No intervention - prednisolone is taken as part if routine clinical care.
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy
Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)
The purpose is to investigate tocilizumab administration in patients with moderately to severely or sight-threatening GO (Graves' ophthalmopathy) without response to treatment with corticoid intravenous pulses.
- Conditions
- Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy, Thyroid Eye Disease
- Trial name
- GRC (NCT01297699)
- Testing
- Tocilizumab (RoActemra®), Sterile 0.9% Sodium Chloride
- Where
- 9 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Thyroid Eye Disease
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202).
- Trial name
- NCT05517447
- Testing
- Observational cohort study, Batoclimab
- Where
- 55 sites in United States, Australia and 12 more
- Volunteers
- 109 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Eye Disease, TED
Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease
Thyroid eye disease frequently causes upper eyelid retraction, which can lead to ocular surface complications and cosmetic concerns.
- Trial name
- TREAT-OT (NCT07471997)
- Testing
- Triamcinolone Acetonide
- Where
- Mexico
- Volunteers
- 29 people
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana